Progress on relationship between Klebsiella pneumoniae pneumonia and interferon signaling pathway

doi:10.3877/cma.j.issn.1674-1358.2024.02.002

Abstract

Abstract:

Klebsiella pneumoniae (Kp) is a common Gram-negative bacterium that causes hospital-acquired and community-acquired infections. Considering the resistance and virulence of Kp, studying its interaction with the interferon signaling pathway is crucial for understanding its pathogenesis and developing new therapeutic strategies. This review discusses the complex relationship between Kp pneumonia and the interferon signaling pathway, which is a core part of the innate immunity that activates various defense genes against pathogens. The activation of the interferon signaling pathway by Kp enhances the antibacterial functions of host immune cells, such as natural killer (NK) cells and macrophages. This review also reveals the synergistic effects of the interferon signaling pathway with the inflammatory and autophagy pathways, which are important for understanding how Kp modulates host immune responses to evade immune surveillance. Finally, this review analyzes the potential applications of the interferon signaling pathway in the treatment of Kp pneumonia. Future research needs to further explore the optimization methods of its therapeutic effects and reduce its side effects, and to cope with this increasingly serious public health issue.

Key words: Klebsiella pneumoniae pneumonia, Interferon, Signaling pathway, Innate immunity

Ruojing Bai, Jun Guo. Progress on relationship between Klebsiella pneumoniae pneumonia and interferon signaling pathway[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(02): 71-74.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2024.02.002

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2024/V18/I02/71

References 34

[1]	Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense[J]. Microbiol Mol Biol Rev,2016,80(3):629-661.
[2]	杭文璐, 杜永亮, 李占结, 等. 免疫功能缺陷患者碳青霉烯类耐药肺炎克雷伯菌院内感染一例[J/CD]. 中华实验和临床感染病杂志(电子版),2022,16(3):205-209.
[3]	Li S, Yu S, Peng M, et al. Clinical features and development of Sepsis in Klebsiella pneumoniae infected liver abscess patients: a retrospective analysis of 135 cases[J]. BMC Infect Dis,2021,21(1):597.
[4]	Shields RK, Zhou Y, Kanakamedala H, et al. Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia[J]. BMC Infect Dis,2021,21(1):572.
[5]	Wu X, Shi Q, Shen S, et al. Clinical and bacterial characteristics of Klebsiella pneumoniae affecting 30-day mortality in patients with bloodstream infection[J]. Front Cell Infect Microbiol,2021,11:688989.
[6]	Luan Y, Sun Y, Duan S, et al. Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever[J]. J Int Med Res,2018,46(11):4596-4604.
[7]	Venkataraman R, Divatia JV, Ramakrishnan N, et al. Multicenter observational study to evaluate epidemiology and resistance patterns of common intensive care unit-infections[J]. Indian J Crit Care Med,2018,22(1):20-26.
[8]	Zhu J, Wang T, Chen L, et al. Virulence factors in hypervirulent Klebsiella pneumoniae[J]. Front Microbiol,2021,12:642484.
[9]	Coates M, Blanchard S, MacLeod AS. Innate antimicrobial immunity in the skin: a protective barrier against bacteria, viruses, and fungi[J]. PLoS Pathog,2018,14(12):e1007353.
[10]	Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine[J]. Nat Rev Drug Discov,2007,6(12):975-990.
[11]	Liu T, Zhang L, Joo D, et al. NF-κB signaling in inflammation[J]. Sig Transduct Target Ther,2017,2(1):17023.
[12]	McNab F, Mayer-Barber K, Sher A, et al. Type Ⅰ interferons in infectious disease[J]. Nat Rev Immunol,2015,15(2):87-103.
[13]	Philips RL, Wang Y, Cheon H, et al. The JAK-STAT pathway at 30: much learned, much more to do[J]. Cell,2022,185(21):3857-3876.
[14]	Tam JCH, Jacques DA. Intracellular immunity: finding the enemy within--how cells recognize and respond to intracellular pathogens[J]. J Leukoc Biol,2014,96(2):233-244.
[15]	Ablasser A, Hur S. Regulation of cGAS- and RLR-mediated immunity to nucleic acids[J]. Nat Immunol,2020,21(1):17-29.
[16]	Ji L, Li T, Chen H, et al. The crucial regulatory role of type Ⅰ interferon in inflammatory diseases[J]. Nat Rev Immunol,2023,13(1):230.
[17]	Shemesh M, Lochte S, Piehler J, et al. IFNAR1 and IFNAR2 play distinct roles in initiating type Ⅰ interferon-induced JAK-STAT signaling and activating STATs[J]. Sci Signal,2021,14(710):eabe4627.
[18]	Stanifer ML, Pervolaraki K, Boulant S. Differential regulation of type Ⅰ and type Ⅲ interferon signaling[J]. Int J Mol Sci,2019,20(6):E1445.
[19]	Platanias LC. Mechanisms of type-Ⅰ- and type-Ⅱ-interferon-mediated signalling[J]. Nat Rev Immunol,2005,5(5):375-386.
[20]	Yang E, Li MMH. All about the RNA: interferon-stimulated genes that interfere with viral RNA processes[J]. Front Immunol, 2020,11:605024.
[21]	Mazewski C, Perez RE, Fish EN, et al. Type Ⅰ interferon (IFN)-regulated activation of canonical and non-canonical signaling pathways[J]. Front Immunol,2020,11:606456.
[22]	Bourdon M, Manet C, Montagutelli X. Host genetic susceptibility to viral infections: the role of type Ⅰ interferon induction[J]. Genes Immun,2020,21(6):365-379.
[23]	Zeng C, Waheed AA, Li T, et al. SERINC proteins potentiate antiviral type Ⅰ IFN production and proinflammatory signaling pathways[J]. Sci Signal,2021,14(700):eabc7611.
[24]	Ivin M, Dumigan A, de Vasconcelos FN, et al. Natural killer cell-intrinsic type Ⅰ IFN signaling controls Klebsiella pneumoniae growth during lung infection[J]. PLoS Pathog,2017,13(11):e1006696.
[25]	Doran CG, Sugisawa R, Carty M, et al. CRISPR/Cas9-mediated SARM1 knockout and epitope-tagged mice reveal that SARM1 does not regulate nuclear transcription, but is expressed in macrophages[J]. J Biol Chem,2021,297(6):101417.
[26]	Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human Protein Atlas[J]. Nat Biotechnol,2010,28(12):1248- 1250.
[27]	Feriotti C, Sá-Pessoa J, Calderón-González R, et al. Klebsiella pneumoniae hijacks the Toll-IL-1R protein SARM1 in a type Ⅰ IFN-dependent manner to antagonize host immunity[J]. Cell Rep,2022,40(6):111167.
[28]	Frank CG, Reguerio V, Rother M, et al. Klebsiella pneumoniae targets an EGF receptor-dependent pathway to subvert inflammation[J]. Cell Microbiol,2013,15(7):1212-1233.
[29]	Cao W, Li J, Yang K, et al. An overview of autophagy: mechanism, regulation and research progress[J]. Bull Cancer,2021,108(3):304-322.
[30]	刘会雪, 张佩佩, 安江科. 三七皂甙R1调节蛋白酪氨酸激酶2/信号转导与转录激活因子3信号通路对肺炎克雷伯菌感染的肺泡上皮细胞损伤的影响[J]. 中国热带医学,2023,23(7):754-760.
[31]	Yanai H, Taniguchi T. Fine-tuning type Ⅰ IFN signaling: a new chapter in the IFN saga[J]. Cell Res,2017,27(12):1407-1408.
[32]	Divangahi M, King IL, Pernet E. Alveolar macrophages and type I IFN in airway homeostasis and immunity[J]. Trends Immunol,2015,36(5):307-314.
[33]	Trevejo-Nuñez G, Lin B, Fan L, et al. Regnase-1 deficiency restrains Klebsiella pneumoniae infection by regulation of a type Ⅰ interferon response[J]. mBio,2021,13(1):e0379221.
[34]	López-Rodríguez JC, Hancock SJ, Li K, et al. Type Ⅰ interferons drive MAIT cell functions against bacterial pneumonia[J]. J Exp Med,2023,220(10):e20230037.

Please choose a citation manager

Content to export